当前位置: X-MOL 学术Lancet HIV › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Health impact, budget impact, and price threshold for cost-effectiveness of lenacapavir for HIV pre-exposure prophylaxis in eastern and southern Africa: a modelling analysis
The Lancet HIV ( IF 12.8 ) Pub Date : 2024-09-20 , DOI: 10.1016/s2352-3018(24)00239-x
Linxuan Wu MHS, David Kaftan MS, Rachel Wittenauer PhD, Cory Arrouzet MPH, Nishali Patel MSc, Arden L Saravis MPH, Brian Pfau BS, Edinah Mudimu PhD, Anna Bershteyn PhD, Monisha Sharma PhD

Injectable lenacapavir administered every 6 months is a promising product for HIV pre-exposure prophylaxis (PrEP). We aimed to estimate the health and budget impacts and threshold price at which lenacapavir could be cost-effective in eastern and southern Africa.

中文翻译:


东部和南部非洲 lenacapavir 用于 HIV 暴露前预防的健康影响、预算影响和成本效益价格阈值:建模分析



每 6 个月注射一次的 lenacapavir 是一种很有前途的 HIV 暴露前预防 (PrEP) 产品。我们旨在估计 lenacapavir 在东部和南部非洲可能具有成本效益的健康和预算影响以及阈值价格。
更新日期:2024-09-20
down
wechat
bug